2026-04-27T03:43:16Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/226102024-11-29T04:30:54Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Uriol Rivera, Miguel G
author
Cabello Pelegrin, Sheila
author
Ballester Ruiz, Maria del Carmen
author
López Andrade, Bernardo
author
Lumbreras, Javier
author
Obrador-Mulet, Aina
author
Perez Montana, Albert
author
Ferreruela Serlavos, Mireia
author
Ayestaran Rota, Jose Ignacio
author
Ferrer Balaguer, Juana Maria
author
Delgado Sanchez, Olga
author
Pallares-Ferreres, Lucio
author
Mas Bonet, Antonio
author
Picado Valles, Maria Jose
author
Ruiz de Gopegui, Rosa
2024-09-06T09:56:40Z
2024-09-06T09:56:40Z
2018-11-02
Uriol Rivera MG, Cabello Pelegrin S, Ballester Ruiz MC, Lopez-Andrade B, Lumbreras Fernández J, Obrador Mulet A, et al. Impact of a multidisciplinary team for the management of thrombotic microangiopathy. PLoS One. 2018 Nov 02;13(11):e0206558.
1932-6203
http://hdl.handle.net/20.500.13003/9030
https://hdl.handle.net/20.500.12105/22610
30388144
10.1371/journal.pone.0206558
PloS One
2-s2.0-85056069800
449289800042
L624736664
Background: Thrombotic microangiopathy (TMA) is an important complication associated with several diseases that are rare and life-threatening. TMA is common to thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). TTP is defined by a severe deficiency of ADAMTS13, and early treatment is associated with good prognosis. The diagnosis of HUS can be difficult due to the potential multiple etiologies, and the best treatment option in most cases is not well-established yet. The implementation of a multidisciplinary team (MDT) could decrease the time to diagnosis and treatment for HUS and may improve the outcomes of these patients. Objective: To determine the impact of MDT on morbidity and mortality [death or chronic renal replacement therapy (CRRT) requirements], incidence and response time [(RT) defined as the period between hospital admission and the first day of direct therapy administration], length of stay at an intensive care unit (ICU-LOS) and total hospitalization (T-LOS) were also assessed. Methods We compared a pre-MDT implementation period (from January/2008 to May/2016) versus post-MDT period (from May/2016 to December/2016). The screening TMA diagnosis was made according the following criteria: hemolytic anemia, thrombocytopenia and acute renal damage and without ADAMTS13 deficiency. An online chat was implemented to provide instant medical information. Results: Twenty-eight patients were included. The incidence changed from 2.3 cases/pre-MDT: (all cases: n = 18) to 10 cases/year post-MDT (all cases: n = 10). Two patients died in pre-MDT and post- MDT (11% versus 20%, P= 0.60). From pre-MDT, the number of patients who required CRRT by post-MDT decreased from 7 (39%) to 0, P= 0.03. Similarly, RT, ICULOS and T-LOS [median(p25-p75)] decreased from 10 (2-12) days to 0.5 (0-1.5) days, P= 0.04, from 16 (9-30) days to 10 (4-13) days, P= 0.01 and from 33 (22-53) days to 16 (1232) days, P < 0.01, respectively. Conclusion: MDT implementation was associated with a greater number of patients who meet TMA criteria. A decrease in the RT and T-LOS periods were observed and associated with better outcomes in these patients.
eng
Impact of a multidisciplinary team for the management of thrombotic microangiopathy
research article